tru Independence’s Cocrystal Pharma COCP Stock Holding History

tru Independence’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-316	Closed	-$5	–	423
2020 Q2	$5	Buy	+316	New	+$3.87K	﹤0.01%	695

Other funds holding COCP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

tru Independence's COCP Position: Q3 2020 in Review

tru Independence sold out of Cocrystal Pharma (COCP) in Q3 2020, closing a stake of 316 shares — an estimated $5 sold.

tru Independence first reported a position in COCP in Q2 2020 and held it in 1 quarter. The position peaked at $5 in Q2 2020. 25 funds tracked by Wall St. Rank hold COCP as of Q3 2020.

tru Independence reported no remaining Cocrystal Pharma position as of Q3 2020 after selling out during the quarter.
tru Independence sold 316 Cocrystal Pharma shares in Q3 2020, an estimated $5.
tru Independence first reported a position in Cocrystal Pharma in Q2 2020 and held it in 1 quarter.
tru Independence's Cocrystal Pharma position peaked at $5 in Q2 2020.
25 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.